RecruitingPhase 1NCT05245500
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- MRTX1719(drug)
- Enrollment
- 336 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2027
Study locations (24)
- Mayo Clinic, Phoenix, Arizona, United States
- Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado, United States
- Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States
- Mayo Clinic, Jacksonville, Florida, United States
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
- Local Institution - 124, Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Brookline, Massachusetts, United States
- Cancer and Hematology Centers of Western Michigan, Norton Shores, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Local Institution - 129, Mineola, New York, United States
- David H Koch, Memorial Sloan Kettering Cancer Center, New York, New York, United States
- New york cancer and blood specialists - Oncology, Port Jefferson Station, New York, United States
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill, North Carolina, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05245500 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited